Risk of venous thromboembolism (VTE) in first degree relatives (FDRS) of patients with unprovoked VTE who do not have factor V Leiden (FVL) or the G20210A prothrombin gene mutation (PGM) Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008
The impact of screening for factor V Leiden (FVL) first degree relatives of patients with venous thromboembolism (VTE) and FVL on their risk of VTE Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010
Factors that predict the risk of recurrent venous thromboembolism (VTE) in patients with VTE and factor V Leiden (FVL) Source: Annual Congress 2010 - Pulmonary embolism Year: 2010
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012
Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006
Correlation of induced sputum (IS) particles size distribution (PDS) and pulmonary function test (PFT) in asthmatics patients (A-pts) Source: Eur Respir J 2004; 24: Suppl. 48, 604s Year: 2004
Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Novel assessment of alpha galactosidase A enzyme (GLA) activity in induced sputum (IS) and blood in patients with Anderson Fabry disease (AFD) Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010
Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction? Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Role of genetic factors in COPD (alpha-1-antitrypsin deficiency and other factors) Source: Annual Congress 2005 - PG13 - COPD: genetic and environmental factors, epidemiology, socio-economic impact and preventative measures Year: 2005
C-reactive protein serum levels, genotypes and the risk of COPD. The Rotterdam study Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD Year: 2008
Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis Source: Eur Respir J 2003; 21: 25-30 Year: 2003
Vitamin D binding protein (DBP) levels during tuberculosis treatment are affected by DBP genotype / haplotype but not by total vitamin D levels Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. Source: International Congress 2017 – COPD biomarkers Year: 2017
Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Endothelial injury in COPD assessed by microalbuminuria (MAB) and von Willebrand factor levels (vWf:Ag) and activity (vWf:Ac) Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Serum levels of thrombopoietin (TPO) in patients with thrombocytosis due to lung cancer and in essential throbocythaemia (ET) Source: Eur Respir J 2001; 18: Suppl. 33, 234s Year: 2001
The G20210A polymorphism of the prothrombin gene is the strong genetic risk factor for the pulmonary embolism development in young patients Source: Eur Respir J 2004; 24: Suppl. 48, 556s Year: 2004
The importance of high plasma levels of factor VIIIc in the severity of pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001